News/Reuters/Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic CancerMarker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic CancerRead the full articleGet unlimited access to articles from Reuters and every other news source on TradingView.Keep reading
